Fidelis Pharmaceuticals, the company that produces Ethiqa XR®, the first FDA-indexed extended-release buprenorphine formulation specifically for mice and rats, recently announced a change to the drug’s storage requirements.
After extensive in-house studies and testing to collect sufficient efficacy data, the company has extended the drug’s storage and use to 90 days post vial broach. Previously, the usage period for broached vials was 56 days.
This change should be reflected on newly purchased Ethiqa XR® within the coming months. Effective immediately, the manufacturer has also advised that bottles already in distribution and labeled with the 56-day expiration date may be used up to the extended 90-day limit.
Important Dosing Reminder
Please consult with your ULAM Faculty Veterinarian and ULAM Husbandry Supervisor
PRIOR TO dosing any animal with Ethiqa XR®. Due to a high incidence of pica, which could cause serious animal health issues, rats given this drug must be housed on paper bedding for 72 hours post-injection.
Questions?
- If you have additional questions about this change, or about using Ethiqa XR® in your mouse/rat studies, please contact your ULAM Faculty Veterinarian.
- Contact the ULAM Business Office at [email protected] or (734) 764-0277 if you need assistance with ordering this product through MWI Animal Health.
Links marked with a lock icon can only be accessed using valid U-M login credentials.